Substance-Specific Treatment
Ibogaine for Kratom & Kratom 7-OH Addiction
The legal opioid crisis hiding in plain sight — and how ibogaine offers a definitive neurological reset
1.7M+
Americans use kratom daily
13x
7-OH potency vs. morphine
80-95%
Withdrawal eliminated by ibogaine
24-36h
Time to symptom resolution
A Hidden Epidemic in Every Gas Station
Kratom 7-hydroxymitragynine (7-OH) shots and extracts are now sold at gas stations, smoke shops, and convenience stores across the United States. Marketed as “natural energy” or a “safe alternative to opioids,” these concentrated products contain a synthetic alkaloid that binds to the same mu-opioid receptors as heroin and fentanyl.
Thousands of people who turned to kratom to escape prescription opioid dependence now find themselves trapped in a new addiction that is, in many cases, harder to quit than the substance they were originally trying to leave behind.
Understanding Kratom and Kratom 7-OH
What Is Kratom?
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia, where its leaves have been used for centuries as a mild stimulant and pain reliever. The plant contains over 40 alkaloids, the two most pharmacologically significant beingmitragynine and7-hydroxymitragynine (7-OH).
In traditional use, fresh leaves are chewed or brewed into tea. At low doses, kratom produces stimulant-like effects. At higher doses, it acts as an opioid agonist, producing sedation, pain relief, and euphoria. While traditional leaf use carries relatively modest addiction potential, the concentrated products flooding the American market are an entirely different substance pharmacologically.
What Is Kratom 7-OH?
7-hydroxymitragynine is the most potent opioid-active alkaloid in the kratom plant, but in natural leaf material it exists in trace amounts (less than 2% of total alkaloid content). What has changed the equation is the commercial production ofconcentrated 7-OH extracts and synthetic 7-OH isolatesthat deliver pharmacologically significant doses of this compound.
Why 7-OH Is Fundamentally Different from Plain Leaf
- 13 times more potent than morphine at mu-opioid receptors (Kruegel et al., 2016, Journal of the American Chemical Society)
- 46 times more potent than mitragynine(the primary kratom alkaloid) as an analgesic
- Produces full opioid agonist effects including respiratory depression at high doses
- Rapid tolerance development requiring dose escalation within weeks
- Severe physical dependence with withdrawal syndrome comparable to traditional opioids
The Deceptive Marketing Problem
Products like “MIT45,” “OPMS Gold,” and various “kratom extract shots” contain concentrated 7-OH at levels thatdo not exist in nature. They are sold as “dietary supplements” with no age verification, no dosing guidance, and no addiction warnings. A single extract shot can contain the opioid equivalent of multiple doses of hydrocodone.
Why Kratom and 7-OH Addiction Is Escalating
Legal and Accessible in Most States
Unlike prescription opioids, kratom and 7-OH products are legal and unregulated in the majority of US states. They require no prescription, no age verification, and are available at an estimated 10,000+ retail locations nationwide. The FDA has issued warnings but has not scheduled kratom as a controlled substance, creating a regulatory vacuum that manufacturers exploit aggressively.
The Opioid-to-Kratom Pipeline
As prescription opioid access has tightened, millions of chronic pain patients and people in recovery have turned to kratom as what they believe is a safer alternative. Many addiction forums, social media groups, and even some healthcare providers have recommended kratom as a “harm reduction” tool. While plain-leaf kratom may carry lower overdose risk than fentanyl, it is not non-addictive, and the escalation to extract products dramatically increases dependence severity.
Rapid Escalation from Leaf to Extract
A common trajectory: a person starts with kratom powder or capsules for pain or energy. Tolerance develops within weeks. Plain leaf no longer works. They switch to extracts — first enhanced powder, then liquid shots containing concentrated 7-OH. Within months, they are spending $50-150 per day on extract products, experiencing severe withdrawal if they miss a dose, and trapped in a cycle that is pharmacologically identical to prescription opioid addiction.
Withdrawal That Rivals Traditional Opioids
Kratom and 7-OH withdrawal produces a syndrome that is clinically similar to opioid withdrawal:
- Severe muscle aches, restless legs, and body-wide pain
- Profuse sweating, chills, and temperature dysregulation
- Nausea, vomiting, and diarrhea
- Extreme anxiety, irritability, and emotional instability
- Insomnia lasting days to weeks
- Depression and anhedonia (inability to feel pleasure)
- Intense cravings that persist for weeks after acute withdrawal subsides
For heavy 7-OH extract users, withdrawal can bemore severe than plain-leaf kratom withdrawaldue to the higher receptor affinity and greater degree of neuroadaptation. Many users report that 7-OH withdrawal feels equivalent to or worse than withdrawal from hydrocodone or oxycodone.
Treatment Gap
Most addiction treatment centers do not recognize kratom dependence as a distinct clinical entity. Patients who seek help are frequently told that kratom “isn’t a real opioid” or are offered generic detox protocols that fail to account for kratom’s unique pharmacology. Many kratom-dependent individuals cycle through multiple failed quit attempts — cold turkey, slow tapers, switching to buprenorphine — before discovering that specialized treatment exists.
How Ibogaine Treats Kratom and 7-OH Addiction
Ibogaine is uniquely suited to treating kratom addiction because it addresses the same opioid receptor systems that kratom and 7-OH have dysregulated. Unlike tapering strategies that prolong suffering over weeks or months, ibogaine interrupts the neurochemical basis of dependence in a single treatment session.
Mu-Opioid Receptor Reset
Kratom and 7-OH produce dependence primarily through mu-opioid receptor agonism. Chronic exposure causes receptor downregulation — the brain reduces receptor density and sensitivity as an adaptive response to constant stimulation. This is why tolerance develops and why withdrawal occurs when the drug is removed.
Ibogaine acts as anon-competitive NMDA receptor antagonist and modulates multiple opioid receptor subtypes (mu, kappa, delta). This multi-receptor interaction:
- Resets mu-opioid receptors to pre-addiction baseline sensitivity
- Interrupts the tolerance cycle that drives dose escalation
- Restores natural endorphin signaling without substitution
- Reverses the receptor downregulation caused by chronic kratom/7-OH use
Rapid Elimination of Withdrawal
The most immediate clinical effect of ibogaine treatment is theelimination of 80-95% of acute withdrawal symptoms within 24-36 hours. For kratom patients, this means:
- Muscle aches and restless leg syndrome resolve during or shortly after treatment
- Gastrointestinal symptoms (nausea, diarrhea) subside within the first day
- Temperature dysregulation and sweating normalize rapidly
- Anxiety and emotional flooding diminish dramatically
- Sleep architecture begins restoring within 48-72 hours (often the last symptom to fully resolve)
Patients frequently describe the experience as waking up “on the other side” of withdrawal — a state that would normally require two to three weeks of acute suffering through conventional detox.
GDNF-Driven Neuroplasticity and Repair
Ibogaine stimulates production ofGlial Cell Line-Derived Neurotrophic Factor (GDNF), a protein critical for the survival and repair of dopamine neurons. Chronic opioid use — including kratom and 7-OH — damages the dopaminergic reward system, contributing to anhedonia, depression, and the inability to experience pleasure from normal activities.
GDNF upregulation promotes neuronal healing, supports the formation of new synaptic connections, and helps restore the brain’s natural reward circuitry. This is not merely symptom suppression — it is structural neurological repair that supports long-term recovery.
Sustained Craving Reduction via Noribogaine
Ibogaine is metabolized in the liver intonoribogaine, a long-acting metabolite that remains pharmacologically active for weeks to months after treatment. Noribogaine provides:
- Extended craving suppression: 70-80% of patients report dramatically reduced or absent cravings for weeks to months
- Mood stabilization: Noribogaine has serotonin reuptake activity that counteracts the depression common in early recovery
- A neuroplasticity window: Enhanced capacity to build new habits and behavioral patterns during the critical early recovery period
Psychological Pattern Interruption
Kratom addiction, like all substance use disorders, is sustained by psychological patterns as much as physical dependence. The ibogaine experience frequently produces profound introspective states in which patients gain direct insight into the emotional drivers of their use — unresolved trauma, avoidance patterns, self-medication of anxiety or depression. This is not psychotherapy in the conventional sense, but many patients describe it as processing years of emotional material in a single session, providing clarity and motivation that persist well beyond the pharmacological effects.
What to Look for in a Kratom Ibogaine Provider
Kratom and kratom 7-OH dependence present unique pharmacological challenges. Not all ibogaine clinics have experience with these substances. When evaluating providers, the following clinical capabilities matter.
Total Alkaloid (TA) Extract
Some specialized providers use Total Alkaloid (TA) extract rather than ibogaine HCL. Most clinics use ibogaine HCL, a single isolated compound typically semi-synthesized fromVoacanga africana, a different African plant. TA extract is derived directly from genuine iboga root bark, preserving all 12+ naturally occurring alkaloids. This full-spectrum approach may produce smoother treatment experiences, more complete withdrawal resolution, and enhanced neuroplasticity compared to single-compound HCL.
Kratom-Specific Protocols
Kratom 7-OH’s higher receptor affinity compared to traditional opioids requires amodified treatment approach. Look for clinics whose medical teams adjust dosing schedules, pre-treatment stabilization, and post-treatment monitoring based on whether patients are using plain-leaf kratom, enhanced extracts, or concentrated 7-OH products — each representing a different level of receptor adaptation.
Why Total Alkaloid Extract Matters for Kratom Patients
The distinction between Total Alkaloid (TA) extract and ibogaine HCL is particularly significant for kratom addiction treatment. Kratom itself is a multi-alkaloid plant — its effects result from the interaction of dozens of compounds. Treating multi-alkaloid dependence with a single isolated compound (HCL) leaves therapeutic gaps that TA’s full spectrum addresses.
| Property | Ibogaine HCL | Total Alkaloid (TA) |
|---|---|---|
| Composition | Single isolated alkaloid | Full spectrum of 12+ alkaloids |
| Receptor Coverage | Primarily mu-opioid, NMDA | Mu, kappa, delta opioid + serotonin + sigma receptors |
| Withdrawal Resolution | Effective for primary symptoms | More complete resolution across symptom domains |
| Treatment Experience | Can be intense, sometimes anxiety-producing | Smoother onset, supported by auxiliary alkaloids |
| Neuroplasticity | GDNF upregulation via ibogaine | GDNF + additional neurotrophic effects from companion alkaloids |
| Availability | Most clinics worldwide | A small number of specialized clinics worldwide |
Critical: SSRI and Antidepressant Warning
A significant percentage of kratom users are also taking SSRIs or other antidepressants. This is common because many people begin using kratom to self-medicate anxiety or depression, often alongside prescribed medications.
SSRIs Must Be Tapered Before Ibogaine Treatment
Ibogaine interacts with serotonin transporters and receptors. Combining ibogaine with SSRIs, SNRIs, or other serotonergic medications creates a risk ofserotonin syndrome — a potentially life-threatening condition involving dangerous elevations in serotonin levels. Common medications that must be discontinued include:
- SSRIs: fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), paroxetine (Paxil)
- SNRIs: venlafaxine (Effexor), duloxetine (Cymbalta)
- Others: tramadol, trazodone, MAOIs, St. John’s Wort
How SSRI Tapering Works Before Ibogaine
Qualified ibogaine providers establish individualized tapering protocols for antidepressants before treatment. The medical team works with each patient to determine appropriate tapering schedules based on medication type, dosage, and duration of use. For medications with long half-lives (such as fluoxetine), a minimum washout period of 6 weeks is required.
Read the complete SSRI tapering guideThe Treatment Process for Kratom Patients
Specialized ibogaine providers follow a structured medical protocol adapted for kratom and 7-OH dependence. The following outlines what a comprehensive kratom treatment program looks like.
Pre-Screening and Medical Evaluation
Before acceptance into the program, all patients undergo comprehensive medical evaluation:
- 12-lead ECG and cardiac evaluation (ibogaine affects QT interval)
- Complete blood panel including liver function, kidney function, and electrolytes
- Full medication and supplement review (identifying contraindicated substances)
- Detailed substance use history — specifically the type of kratom product, daily dosage, duration of use, and whether 7-OH extracts are involved
- Psychological assessment and readiness evaluation
Stabilization Period
Patients arrive at the clinic 1-2 days before the ibogaine session for stabilization:
- Medical team assesses current withdrawal status using the Clinical Opiate Withdrawal Scale (COWS)
- Hydration, nutritional support, and electrolyte optimization
- Comfort medications as needed (non-contraindicated) to manage early withdrawal
- For 7-OH patients: careful monitoring of withdrawal onset timing, as concentrated extracts may have different elimination kinetics
- Psychological preparation and setting of therapeutic intention
Ibogaine Flood Dose
The primary treatment session using Total Alkaloid extract:
- Test dose administered first to assess individual sensitivity and rule out allergic reaction
- Full flood dose calculated based on body weight, substance use history, and medical profile
- Continuous cardiac monitoring (ECG, pulse oximetry, blood pressure) throughout the 18-36 hour active period
- Medical staff present at all times with emergency protocols established
- For heavy 7-OH users: dosing may be adjusted upward or supplemental booster doses may be administered to fully address the deeper receptor adaptation
Integration and Aftercare
Recovery does not end when the ibogaine wears off:
- 2-4 days of post-treatment medical observation and rest
- Integration therapy sessions to process the ibogaine experience and establish recovery framework
- Individualized aftercare plan including therapy recommendations, lifestyle modifications, and relapse prevention strategies
- Guidance on managing post-acute withdrawal symptoms (PAWS) which may persist for weeks in some patients
- Booster dose options discussed for patients who may benefit from follow-up treatment at 3-6 months
Special Considerations for Kratom 7-OH Patients
Patients using concentrated 7-OH products present unique clinical challenges that require protocol modifications:
Higher Receptor Affinity
7-OH binds to mu-opioid receptors with greater affinity than mitragynine, requiring more aggressive receptor reset. The ibogaine dosing protocol is adjusted upward for patients who have been using high-potency 7-OH extracts to ensure comprehensive receptor occupancy and reset.
Withdrawal Timeline Variability
7-OH products vary widely in potency and formulation. Liquid shots, enhanced capsules, and powdered extracts each produce different elimination kinetics. The medical team carefully assesses onset and severity of withdrawal to optimize the timing of ibogaine administration.
Polysubstance Screening
7-OH products are often used alongside other substances — plain-leaf kratom, phenibut, benzodiazepines, or alcohol. Each co-used substance affects ibogaine safety and dosing. Full disclosure and comprehensive drug screening are essential before treatment proceeds.
Extended Monitoring
Due to the higher potency of 7-OH and the greater degree of neuroadaptation it produces, patients using these products may require longer post-treatment observation and may benefit from an additional booster dose 24-48 hours after the initial treatment to address any residual withdrawal.
Outcomes and Clinical Evidence
While ibogaine research for kratom-specific addiction is still emerging, the pharmacological overlap between kratom/7-OH and traditional opioids means that the extensive ibogaine-opioid literature applies directly. Clinical observations from ibogaine treatment providers confirm strong outcomes for kratom patients.
Reported Outcomes for Kratom Patients
- 80-95% report elimination of acute withdrawal symptoms within 24-36 hours
- 70-80% report significantly reduced or absent cravings lasting weeks to months
- 50-65% maintain abstinence at 12-month follow-up (with integration work and aftercare)
- Patients report restoration of natural energy, mood, and motivation within the first week — functions that kratom had been artificially providing
“I was spending $100 a day on OPMS Gold shots. I couldn’t go four hours without one or the withdrawal would start. I tried to quit cold turkey twice and couldn’t make it past day three. After ibogaine, I woke up the next morning and the withdrawal was just gone. Not reduced — gone. That was seven months ago and I haven’t touched kratom since.”
— 31-year-old male, kratom 7-OH extract user, 3 years
“I started kratom to get off Percocet after a surgery. Within six months I was on extracts and spending more than I ever spent on pills. The worst part was everyone telling me kratom was ‘natural’ and ‘safe.’ The ibogaine treatment gave me my life back. The TA extract they use made the whole experience smoother than I expected.”
— 42-year-old female, transitioned from prescription opioids to kratom extracts
Note: Individual outcomes vary. Testimonials represent individual experiences and are not guarantees of treatment results. Consult qualified medical professionals before pursuing any treatment.
Kratom Quit Methods Compared
| Method | Duration | Withdrawal | Success Rate | Notes |
|---|---|---|---|---|
| Ibogaine (TA) | 5-7 days | Eliminated (24-36h) | 50-65% at 12 months | Full receptor reset; sustained craving relief |
| Cold Turkey | 7-21 days acute | Severe, unmanaged | 10-20% | High relapse during acute phase; PAWS for months |
| Gradual Taper | 4-12 weeks | Prolonged, moderate | 20-30% | Requires discipline; many stall or escalate |
| Suboxone Bridge | Ongoing | Managed via substitution | Variable | Trades one dependence for another; difficult to taper |
| Stem & Vein Taper | 2-6 weeks | Moderate | 15-25% | Kratom-community method; limited evidence |
Safety, Screening, and Contraindications
Ibogaine is a powerful medicine that requires rigorous medical oversight. It is not appropriate for everyone, and safety depends on thorough screening and proper clinical protocols.
Absolute Contraindications
Ibogaine treatment is not safe for patients with:
- Cardiac conditions: prolonged QT interval, arrhythmias, cardiomyopathy, or heart failure
- Severe hepatic (liver) or renal (kidney) impairment
- Active or uncontrolled seizure disorder
- Active psychosis, schizophrenia, or severe untreated psychiatric conditions
- Pregnancy or breastfeeding
- Concurrent use of contraindicated medications (SSRIs, SNRIs, MAOIs, certain antipsychotics — see SSRI section above)
Required Pre-Treatment Screening
- 12-lead ECG with QTc interval measurement (QTc above 450ms in males or 470ms in females is typically exclusionary)
- Comprehensive metabolic panel: liver enzymes (AST, ALT), kidney function (BUN, creatinine), electrolytes (potassium, magnesium, calcium)
- Complete blood count and coagulation studies
- Urine drug screen confirming substances used and absence of contraindicated compounds
- Detailed medication review (over-the-counter, prescription, and supplement)
- Psychological readiness assessment
Post-Treatment Overdose Risk
If you relapse after ibogaine treatment, your opioid tolerance has been reset.The dose of kratom or 7-OH you were using before treatment may now produce dangerous effects. This applies to all opioid agonists, not just kratom. If relapse occurs:
- Start at a fraction of your previous dose
- Never use alone
- Have naloxone (Narcan) available
- Contact your treatment provider immediately
Ready to Break Free from Kratom?
Specialized ibogaine providers have direct clinical experience treating kratom and 7-OH dependence. Use our pre-screening tool to determine whether ibogaine treatment is appropriate for your situation, then explore verified clinics.
Frequently Asked Questions: Kratom and Ibogaine
Is kratom really addictive? I was told it was natural and safe.
Kratom is natural in the same way that opium and cocaine are natural — derived from plants, but pharmacologically active at opioid receptors. Plain-leaf kratom at low doses carries moderate addiction potential. However, concentrated extracts and 7-OH products produce dependence that is clinically comparable to prescription opioid addiction. The “natural and safe” marketing is misleading and has led many people into severe dependence.
Does ibogaine work differently for kratom than for heroin or fentanyl?
The fundamental mechanism is the same — ibogaine resets opioid receptors regardless of which opioid agonist caused the adaptation. However, kratom and especially 7-OH have unique receptor binding profiles (partial agonism with mitragynine, stronger agonism with 7-OH). Treatment protocols may be adjusted based on the specific products used and the severity of dependence. In general, kratom patients experience slightly less severe acute withdrawal than fentanyl patients, which can translate to a smoother ibogaine treatment experience.
How long do I need to be off kratom before ibogaine treatment?
The medical team will provide specific guidance based on your usage pattern. Generally, patients are asked to use their last dose 12-24 hours before the ibogaine session, allowing mild withdrawal to begin. This ensures the opioid receptors are in a state where ibogaine can most effectively engage them. The timing is different from fentanyl (which requires longer clearance) and is adjusted for 7-OH extract users whose withdrawal onset may differ from plain-leaf users.
I am taking an SSRI alongside kratom. Can I still do ibogaine?
Yes, but not while on the SSRI. You must taper off serotonergic medications before ibogaine treatment. The required washout period depends on the specific medication — some require 2-3 weeks, fluoxetine (Prozac) requires at least 6 weeks due to its long half-life. A qualified ibogaine clinic will work with you to create a safe tapering schedule. See ourSSRI tapering guidefor comprehensive information.
What makes Total Alkaloid (TA) extract better than ibogaine HCL for kratom?
Kratom itself is a multi-alkaloid substance, meaning dependence involves adaptation across multiple receptor systems — not just the primary mu-opioid pathway. TA extract addresses this complexity with its full complement of iboga alkaloids, each acting on different receptor subtypes. Patients treated with TA report more complete symptom resolution, a smoother treatment experience, and more sustained craving reduction compared to clinical reports of HCL-only treatment. TA extract is offered by a small number of specialized providers globally.
How much does ibogaine treatment for kratom addiction cost?
Treatment costs typically range from $7,500 to $12,000 depending on the length of stay and protocol required. Insurance does not currently cover ibogaine treatment. However, when compared to the ongoing cost of kratom extract use ($50-150/day, or $18,000-55,000/year) and repeated failed quit attempts, ibogaine treatment represents a significant economic value. Visit thecost guidefor detailed pricing information.
Is ibogaine treatment safe? What are the risks?
Ibogaine carries real medical risks, primarily cardiac. Ibogaine affects cardiac conduction (QT prolongation), which is why rigorous pre-treatment cardiac screening is mandatory. In a properly screened patient treated at a medically equipped facility with continuous cardiac monitoring, the safety profile is well-established. The greatest risk factor is treatment at unqualified facilities without proper screening or monitoring. Always verify that any clinic you consider has on-site medical staff, cardiac monitoring capability, and emergency protocols. See oursafety guidefor comprehensive information.
Will I need more than one ibogaine treatment?
Most kratom patients achieve significant results from a single flood dose treatment. However, some patients — particularly long-term 7-OH extract users or those with concurrent psychological conditions — may benefit from a booster treatment at 3-6 months. The medical team will discuss follow-up options based on your individual response and recovery trajectory.
Why is ibogaine treatment done in Mexico and not in the United States?
Ibogaine is classified as a Schedule I substance in the United States, making it illegal to administer clinically. Mexico has no such restriction, and a number of medically supervised clinics operate legally there. Reputable clinics in Mexico operate under full medical licensure with experienced staff, hospital-grade monitoring equipment, and established emergency protocols. Many American and Canadian patients travel to Mexico specifically for ibogaine treatment due to its legal availability and the quality of specialized clinics.
Kratom Does Not Have to Control Your Life
Whether you started kratom to manage pain, escape prescription opioids, or simply out of curiosity — and whether you are using plain leaf or concentrated 7-OH extracts — ibogaine offers a path to genuine freedom that no taper schedule or willpower-based approach can match.
Specialized ibogaine providers in Mexico offer medically supervised protocols adapted for kratom dependence, with experienced teams and comprehensive cardiac monitoring.